Therapeutic Indications

Pilof is a pharmacological agent primarily utilized in the management of elevated intraocular pressure. It is specifically indicated for the treatment of conditions where maintaining controlled fluid pressure within the eye is necessary to prevent optic nerve damage.

Open-Angle Glaucoma

The primary application of Pilof is in the management of open-angle glaucoma. In this chronic condition, the eye's drainage system becomes less efficient over time, leading to a gradual increase in intraocular pressure. Pilof works by facilitating the outflow of aqueous humor, the fluid produced within the eye, thereby helping to maintain pressure within a stable range.

Ocular Hypertension

Pilof is also used for individuals diagnosed with ocular hypertension. This condition is characterized by intraocular pressure levels that are higher than the standard range, even in the absence of detectable optic nerve damage or vision loss. By lowering this pressure, the medication serves as a preventative measure to reduce the risk of progressing to glaucoma.

Mechanism of Action and Benefits

Pilof belongs to a class of medications known as miotics or cholinergic agonists. Its therapeutic benefits are derived from its ability to mimic the action of natural substances in the body that stimulate specific receptors in the eye.

• Contraction of the Ciliary Muscle: The medication induces the contraction of the ciliary muscle. This action physically opens the trabecular meshwork, which is the primary drainage pathway for fluid in the eye.
• Improved Fluid Drainage: By widening these drainage channels, Pilof enhances the rate at which aqueous humor exits the eye, leading to a consistent reduction in internal pressure.
• Pupillary Constriction: As a miotic, the medication causes the pupil to constrict. In certain anatomical configurations, this can help pull the iris tissue away from the drainage angles, further supporting fluid movement.

Clinical Goals

The fundamental objective of treatment with Pilof is the long-term stabilization of intraocular pressure. By achieving and maintaining target pressure levels, the medication helps to preserve visual function and protect the integrity of the optic nerve over time.

Regulatory References

1. Health Canada product information

Pilof (mifepristone) eligibility is strictly defined by government regulatory labeling, specifying groups who must not use the medicine and populations requiring special consideration.

Contraindications and Exclusions

The medicine is contraindicated (must not be used) for patients with a confirmed hypersensitivity to Pilof or its components, chronic adrenal failure, inherited porphyria, and those on long-term corticosteroid therapy. For its use in pregnancy termination, confirmed or suspected ectopic pregnancy or an intrauterine device (IUD) in place are absolute exclusions.

Use in Specific Populations

Population Group	Regulatory Status
Pregnancy	Contraindicated for certain indications (e.g., control of hyperglycemia); Restricted by gestational age (e.g., up to le 70 days) for other uses.
Breastfeeding	Avoidance is recommended during long-term therapy. For single-dose use, interruption may not be required per limited data.
Severe Hepatic Impairment	Use is not recommended due to lack of established safety and efficacy data.
Renal Impairment	Caution is advised due to a lack of formal studies in this group.
Pediatric Patients	Safety and efficacy have not been established in the general pediatric population.

Official labeling mandates that eligibility is conditional on the absence of these prohibited factors and a thorough assessment of the patient's specific health status.

The official regulatory profile for Pilof (Diosmin/Hesperidin) is characterized by a documented absence of reported interactions with other medicinal products. Regulatory authorities state that no specific interaction studies have been formally conducted and that no clinically relevant drug interactions have been reported since the marketing of this specific Micronized Purified Flavonoid Fraction formulation.

This official documentation means the prescribing information does not list any substances or drug classes that are formally classified as contraindicated due to an interaction risk.

Interaction Scope	Official Regulatory Information
Medicinal Product Interactions	None documented as clinically relevant.
Mechanistic Basis (e.g., CYP/Transporters)	No specific pharmacokinetic or pharmacodynamic interaction mechanisms are documented in regulatory texts.
Timing Rules	None. No mandatory timing separation is required for co-administration.
Food, Alcohol, or Supplements	No interaction documented.
Interaction-Related Restrictions	No formal 'do-not-combine' rules or restrictions are documented based on drug interaction risk.

The regulatory finding of "no clinically relevant interaction reported" confirms that there are no official label requirements for dose adjustment, monitoring, or restricted co-administration for Pilof. The structure of the interaction profile is therefore defined by the lack of specific, officially documented constraints. This regulatory position applies across medicinal product categories.

Modulation of Venous Tone and Fluid Dynamics

Pilof's mechanism involves a synergistic, multi-target action focused on influencing the peripheral venous and microcirculatory systems. The active components, Diosmin and Hesperidin, engage complementary mechanistic domains to influence the function of the peripheral blood vessels.

This mechanism targets venous smooth muscle cells and their response to norepinephrine. The process is thought to prolong norepinephrine's effect, promoting a sustained contractile response in the vein walls and potentially increasing their elasticity. Concurrently, the drug acts on the lymphatic capillaries to stimulate their intrinsic contractility, augmenting the clearance of interstitial fluid. This combined action promotes increased venous tone and augments the clearance of interstitial fluid.

Protection of the Microvascular Barrier

This mechanism focuses on stabilizing the integrity of the endothelial cells that line the small blood vessels. The drug exerts anti-inflammatory and anti-oxidant activity, specifically by reducing the expression of adhesion molecules and suppressing key inflammatory signaling pathways. This action protects the capillaries from leukocyte-mediated interactions. The resulting physiological consequence is a reduction in capillary hyperpermeability, restricting the outward filtration of fluid and proteins across the endothelial barrier.

How to Use Pilof: Official Administration Guidelines

Pilof, containing a Micronized Purified Flavonoid Fraction (MPFF), is administered exclusively via the oral route as a film-coated tablet. Official administration instructions emphasize that the tablet must be swallowed whole and should not be crushed or chewed. This procedural constraint ensures the proper absorption of the micronized active compounds.

---

Official Dosing and Scheduling

Administration guidelines define two distinct dosing schedules based on the context of use:

• Chronic Venous Symptoms: The established maintenance dose is 1000 mg of the MPFF per day. This regimen is often intended for sustained use, spanning several months, and the daily dose may be taken once or divided into two separate administrations.

• Acute Hemorrhoidal Crisis: A short-term, sequential dosing regimen is employed. This course begins with a high dose of 3000 mg per day, administered in three divided doses, for the initial four days. This is followed by a reduced dose of 2000 mg per day, administered in two divided doses, for the subsequent three days. The total duration of this regimen is a fixed seven-day course.

---

Administration Conditions and Procedures

Feature	Procedural Requirement
Timing in Relation to Meals	Doses are officially instructed to be taken at mealtimes (e.g., lunch and/or dinner).
Tablet Integrity	Tablets must be swallowed whole with water.
Population Adjustments	Primary regulatory documents do not specify official dose adjustments for older adults or patients with renal or hepatic impairment.

The official instructions structure the use of the drug by defining both the milligram dosage and the required frequency based on the usage scenario, ensuring adherence to the regulatory-approved procedure.

Research evidence / Overview of studies for Pilof (Diosmin/Hesperidin)

Evidence for Use in Managing Symptoms of Chronic Venous Insufficiency (CVI)

Research for Pilof in conditions characterized by Chronic Venous Insufficiency (CVI) has been documented in various studies, including Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. Researchers primarily studied adult patients with symptomatic CVI, focusing on how the formulation was observed in conditions characterized by functional limitations. The trials were designed to examine outcomes related to physical discomfort.

Studies were conducted during periods of increased symptom activity, and research highlights changes measured during the study period related to patient-reported outcomes describing perceived discomfort. Specific symptoms that researchers monitored included the intensity of leg heaviness, pain, and night cramps. Research so far indicates that findings describe patterns observed in the studies across key measurements of physical discomfort and swelling.

The research landscape is characterized by multiple RCTs and systematic reviews that focus on short-term symptomatic change. However, many of the clinical trials conducted have limited follow-up durations. This means that while research has explored short-term changes, long-term effects are not fully established regarding sustained patterns of use for this chronic condition over many years.

---

Evidence for Use in Acute Hemorrhoidal Crisis

Research for Pilof in conditions characterized by acute hemorrhoidal crisis also includes a number of Randomized Controlled Trials, as well as systematic reviews. This evidence is relevant in trials assessing short-term or episodic symptom patterns, particularly focusing on conditions associated with acute or disruptive episodes. These studies were conducted during periods of heightened symptom activity.

Studies explored outcomes related to inflammatory or irritative states. Researchers mainly monitored the intensity of symptoms such as pain, bleeding, and observable local swelling over very defined and short time intervals. Findings indicate that studies report how symptoms evolved in the observed populations during the rapid, acute phase of the crisis. Data for certain groups remain insufficient, especially concerning outcomes related to the prevention of future crises or for patients with very severe or complicated acute episodes.

---

Gaps and Uncertainties in the Research Evidence

The available research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. One key limitation is the variability in the formulation and dosing sometimes observed across the entire body of literature on flavonoids, which can make it challenging to compare results directly. Furthermore, comparative evidence is limited in some areas, meaning research has not always explored how Pilof compares directly to every other studied approach for CVI symptoms over the long term. As noted, long-term effects are not fully established.

Key Studies & References Diosmin Monograph (Alternative Medicine Review)

Common questions about Pilof (FAQ)

Q: Is the 7-day dosing schedule for hemorrhoids the same every time I have a flare-up?

A: The official product labeling defines the dosage for an acute hemorrhoidal crisis as a specific, sequential seven-day course, meant for a single episode. If another crisis occurs, re-initiating the treatment is a matter for clinical judgment. The information specifies the proper dosage for the acute course, but a physician determines when to restart.

---

Q: How long am I allowed to take Pilof for chronic venous problems?

A: Regulatory documents state that for chronic venous symptoms, the medicine is taken as a maintenance dose, often intended for sustained use spanning several months. However, the official product information does not define a specific, mandatory maximum duration for chronic use. The current research evidence notes that long-term effects over many years are not fully established.

---

Q: What happens if I miss a dose of Pilof?

A: Official product information suggests taking a missed dose as soon as it is remembered. However, if the next dose is near, the recommendation is to skip the missed dose and resume the usual schedule. It is advised to never take two doses at the same time.

---

Q: What happens if I accidentally take too much Pilof (overdose)?

A: If too much Pilof is taken, regulatory safety data indicate that this may intensify the reported side effects, which are primarily related to the gastrointestinal system. In the event of a suspected overdose, it is essential to contact a healthcare professional or a poison control center immediately.

---

Q: Why is the micronization process so important for the drug to work?

A: The official product composition information explains that the micronized preparation is crucial because it enhances the poor solubility of the active compounds. This specialized process is necessary to improve absorption in the intestine and support the medicine's therapeutic effect.

---

Q: Is Pilof approved for patients who are recovering from vein surgery?

A: The official indications for Pilof are the symptoms of Chronic Venous Insufficiency (CVI) and acute hemorrhoids. However, some regulatory summaries reference clinical studies suggesting that the product has been used to complement other procedures, such as surgery. Any use for this purpose would be based on the treating physician’s assessment and judgment.

---

Q: What is the difference between Pilof and a standard Diosmin supplement?

A: Pilof is formally classified as a pharmaceutical product by regulatory bodies, unlike standard Diosmin products, which are often classified as supplements. The key difference is the specific pharmaceutical classification and the micronization process, which is intended to enhance absorption compared to non-micronized forms.

The official regulatory guidelines for Pilof (Diosmin/Hesperidin) specify mandatory requirements for its storage and disposal to ensure stability and public safety.

Official Storage and Handling

Condition	Regulatory Requirement
Temperature	Store at temperatures not exceeding 30 C (86 F), consistent with room temperature.
Protection	Keep the product protected from light and moisture.
Container	Must be kept in the original carton or blister packaging.
Child Safety	Keep this medicine out of the sight and reach of children.
Prohibited Use	Do not use the medicine after the expiry date shown on the packaging.

Official Disposal Rules

The disposal mandate strictly prohibits discarding the medicine via wastewater or household waste. Patients are instructed to consult a pharmacist for guidance on local take-back schemes or proper methods to throw away unused medicine, which helps protect the environment from contamination.